S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Henry Ford Would NEVER Have Seen This Coming (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Henry Ford Would NEVER Have Seen This Coming (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Henry Ford Would NEVER Have Seen This Coming (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Henry Ford Would NEVER Have Seen This Coming (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company

Cytokinetics Stock Price, News & Analysis (NASDAQ:CYTK)

$32.56
-1.33 (-3.92%)
(As of 12/5/2023 ET)
Compare
Today's Range
$32.54
$33.93
50-Day Range
$26.88
$36.32
52-Week Range
$25.98
$47.49
Volume
1.22 million shs
Average Volume
1.05 million shs
Market Capitalization
$3.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.87

Cytokinetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
83.9% Upside
$59.87 Price Target
Short Interest
Bearish
14.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
-0.32mentions of Cytokinetics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2.33 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.74) to ($4.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

288th out of 948 stocks

Pharmaceutical Preparations Industry

114th out of 421 stocks


CYTK stock logo

About Cytokinetics Stock (NASDAQ:CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Stock Price History

CYTK Stock News Headlines

Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Cytokinetics Inc
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Expert Ratings for Cytokinetics
Cytokinetics Inc (CYTK) Reports Q3 2023 Financial Results
Cytokinetics Reports Third Quarter 2023 Financial Results
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTK
Employees
409
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$59.87
High Stock Price Target
$80.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+83.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

Net Income
$-388,950,000.00
Net Margins
-6,736.12%
Pretax Margin
-6,739.96%

Debt

Sales & Book Value

Annual Sales
$7.82 million
Book Value
($1.14) per share

Miscellaneous

Free Float
94,328,000
Market Cap
$3.19 billion
Optionable
Optionable
Beta
0.57

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives















CYTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price target for 2024?

15 equities research analysts have issued 1-year price objectives for Cytokinetics' shares. Their CYTK share price targets range from $42.00 to $80.00. On average, they predict the company's stock price to reach $59.87 in the next twelve months. This suggests a possible upside of 83.9% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2023?

Cytokinetics' stock was trading at $45.82 at the beginning of the year. Since then, CYTK shares have decreased by 28.9% and is now trading at $32.56.
View the best growth stocks for 2023 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) announced its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.63. The biopharmaceutical company earned $0.38 million during the quarter, compared to the consensus estimate of $24.71 million.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (12.23%), Wellington Management Group LLP (8.15%), American Century Companies Inc. (2.27%), Invesco Ltd. (1.21%), Northern Trust Corp (1.09%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CYTK) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -